WO2007007347A1 - Industrial process of fexofenadine hydrochloride with controlled side products - Google Patents

Industrial process of fexofenadine hydrochloride with controlled side products Download PDF

Info

Publication number
WO2007007347A1
WO2007007347A1 PCT/IN2005/000241 IN2005000241W WO2007007347A1 WO 2007007347 A1 WO2007007347 A1 WO 2007007347A1 IN 2005000241 W IN2005000241 W IN 2005000241W WO 2007007347 A1 WO2007007347 A1 WO 2007007347A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
methanol
fexofenadine
ketone
mixture
Prior art date
Application number
PCT/IN2005/000241
Other languages
French (fr)
Inventor
Siddiqui Mohammed Jaweed Mukarram
Aravind Yekanathsa Merwade
Anjum Reyaz Khan
Pawan Vrajlal Solanki
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Publication of WO2007007347A1 publication Critical patent/WO2007007347A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Definitions

  • the present invention relates to the robust, economically feasible and environmentally friendly manufacturing process of Anhydrous Fexofenadine Hydrochloride (I) with controlled level of side products.
  • Anhydrous Fexofenadine Hydrochloride (I) with controlled level of side products.
  • the second aspect of the present invention is to furnish Fexofenadine Hydrochloride with controlled level of water content, i.e., not more than 0.5% using acetone as a solvent of choice for dehydration.
  • the present invention relates to a purification method of the crude product to get acceptable quality of Fexofenadine Hydrochloride.
  • the present invention reports the robust manufacturing process for the production of Fexofenadine Hydrochloride having less than 1.0% of total impurities and moisture content less than 0.5 % .
  • the characterization of the known impurities, i.e. , Fexofenadone and meta- isomer of Fexofenadine has been done by IR, NMR ( 1 H and C 13 ), LC MS MS and HPLC impurity profile gradient method.
  • the manufacturing process starts from the ⁇ , ⁇ -Dimethylphenyl acetic acid.
  • ⁇ , ⁇ - Dimethylphenyl acetic acid on treatment with methanol in presence of concentrated sulfuric acid in catalytic amount provides the methyl ester of ⁇ , ⁇ -Dirnethylphenyl acetic acid, i.e., methyl- ⁇ , ⁇ -Dimethylphenyl acetate .
  • the Fexofenadone methyl ester is reduced with sodium borohydride in methanol, which on subsequent alkaline hydrolysis in water methanol mixture gives Fexofenadine having para and meta isomer.
  • the present invention relates to a process for the efficient purification method of Fexofenadine and its hydrochloride salt having less than 1.0% of total impurities and moisture content less than 0.5%.
  • the characterization of the known impurities, i.e., Fexofenadone and meta-isomer of Fexofenadine has been done by IR, NMR ( 1 H and C 13 ), LC MS MS and HPLC impurity profile gradient method.
  • the present invention is directed to a manufacturing process of 4-[4-[4-(hydroxydiphenylmethyl)-l-piperidinyl]-l-hydroxybutyl]- ⁇ , ⁇ - dimethylbenzene acetic acid hydrochloride in pure form.
  • the schematic presentation of synthetic process of fexofenadine hydrochloride is shown in Scheme I.
  • Fexofenadine hydrochloride Anhydrous Fexofenadine hydrochloride
  • crude fexofenadine metal and para isomers
  • Methyl- ⁇ , ⁇ -dimethylphenylacetic acid on Fridel-Craft's acylation with 4-chlorobutyryl chloride in presence of anhydrous aluminum chloride in ethylene dichloride produced acylated Methyl- ⁇ , ⁇ -dimethylphenyl acetic acid, i.e., ketone intermediate as meta and para- isomers.
  • Methyl-4-(4-chloro-l-oxobutyryl)- ⁇ , ⁇ -dimethyl ⁇ henyl acetate (Ketone) (meta and para isomers) was dissolved in toluene followed by addition of Azacyclanol and water in presence of potassium carbonate and potassium iodide. Reaction mixture was refluxed for about 30 to 40 hours. After the reaction was completed, reaction mixture was cooled to room temperature and aqueous layer was discarded.
  • Methyl-4-(4-Chloro-l-oxobutyryl)- ⁇ , ⁇ -dimethylphenyl acetate, (Ketone) (meta and para isomers) was dissolved in dimethyl formamide followed by addition of Azacyclnol, potassium carbonate and potassium iodide.
  • the reaction mixture was heated at 90 18 C for about 7 to 12 hours. Reaction was monitored by HPLC. After the reaction was completed it was cooled to room temperature and the product was extracted with chloroform and was well washed with water. Removal of the organic solvent at reduced pressure yielded thick oily carbinol.
  • Methyl-4 ⁇ 4-[4-(hydroxydiphenylmetyl)-l-piperidinyl ⁇ -l-hydroxybutyl]- ⁇ , ⁇ - dimethylbenzene acetate (carbinol) obtained as oily mass in example 3 was dissolved in methanol and cooled to about 0 to 20 ® C followed by addition of sodium borohydride. At the same temperature reaction mass stirred for 2 to 5 hours. After the reduction was completed the reaction mass was stirred at room temperature in presence of water and chloroform. Organic layer was separated followed by rewashing with aqueous layer.
  • the dicarbinol prepared in example 3 was dissolved in methanol followed by addition of sodium hydroxide in potable water followed by refluxed for about 3 to 6 hours. Methanol was distilled off, once the reaction deprotection was completed. The reaction mixture was cooled to room temperature and to it chloroform was added. Reaction mixture was cooled to about 0 to 2O 0 C. pH of the reaction mass was adjusted to about 6.4 to 6.8 with 50 % aqueous hydrochloric acid solution. Reaction mixture was stirred for 1 hour at the same pH. Chloroform was separated and aqueous layer was washed twice with chloroform. Organic layer was pooled and submitted for distillation under reduced pressure.
  • Fexofenadine (40 Kg) thus isolated from the above step was charged to about 60 to 100 Ltr of a mixture of methanol in methylethyl ketone in volume ratio of 0.3 to 5.0. More particularly, the volume ratio of methanol in methylethyl ketone was 0.4 to 2.0, specifically about 0.4 to 0.6.
  • the reaction mass was refluxed for about 10 minutes to 2 hours, more particularly between about 20 minutes to 40 minutes. After the said time reaction mass was cooled to room temperature followed by stirring for another 1 hour at room temperature. The reaction mixture was centrifuged. The same treatment was repeated twice followed by treatment with dimethyl formamide-methanol and water.
  • Three times treated fexofenadine base in the above step was charged to about 120 to 180 Ltr of a mixture of methanol in DMF volume ratio of 0.3 to 5.0. More particularly, the volume ratio of methanol was 0.4 to 2.0. More particularly, the volume ratio of methanol in DMF was about 0.4 to 0.6.
  • the reaction mixture was refluxed for about 10 minutes to 2 hours, more particularly between about 30 minutes to 1.5 hours. After the said time reaction mixture was cooled to room temperature and centrifuged.
  • Fexofenadine base having moisture content about 2.5 to 6% was taken in methanol and treated with 50 % aqueous HCl to make the pH of the solution between 2.4 to 2.6.
  • the clear solution was filtered to remove any solid contaminant.
  • Chilled potable water was added to the solution at 0 to 20°C.
  • the hydrochloride salt of fexofenadine was obtained as white crystals. Additional volume of water was added to the reaction mixture at the same temperature and stirred for 2 hours. Material was centrifuged and dried.
  • the fexofenadine hydrochloride obtained in the above step was treated with acetone for about 30 minutes to 2 hours between about 4O 0 C to reflux temperature.
  • the reaction mixture was cooled to 0 to 5°C and centrifuged. Centrifuged material was dried in FBD for 6 to 8 hours at 60 to 8O 0 C to get the title product having moisture content between about 0.2 to 0.5% .
  • Methyl-4-(4-chloro-l-oxobutyryl)- ⁇ , ⁇ -dimethyl phenyl acetate (Ketone) 70 Kg (0.2482 Kmole) was dissolved in 500 to 700 Ltr toluene and to it was added Azacyclanol, 50 to 60 Kg followed by potassium bicarbonate, 74 Kg (0.7391 Kmole) and potassium iodide, 0.50 to 1.20 Kg. Finally, to it was added 53 Ltr water. Reaction mixture was refluxed for 30 to 40 Hours. Completion of the reaction was monitored by HPLC. On completion the reaction mixture was cooled to room temperature and aqueous layer was discarded. Toluene layer was filtered through Nutsche. Finally toluene was distilled under reduced pressure and degassed for 2 hours to get the oily mass of carbinol.
  • Carbinol (Methyl-4 ⁇ 4-[4-(hydroxydiphenyhnetyl)-l-piperidinyl ⁇ -l-oxobutyl]-a, a- dimethylbenzene acetate)
  • Reaction mixture was heated at 9O 0 C for 7 to 2 Hours. Completion of the reaction was monitored by HPLC. On completion the reaction mixture was cooled to room temperature and the product was extracted twice with chloroform and finally washed with water. Removal of the solvent at reduced pressure provides thick oily carbinol.
  • Fexofenadine base obtained after third purification was treated with a mixture of 100 Ltr dimethylformamide and 50 Ltr methanol and heated at reflux for an hour. Then cooled to room temperature and centrifuged.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

The present invention relates to a process for the preparation of Anhydrous Fexofenadine Hydrochloride with controlled level of side products. Another aspect of the present invention is purification of Fexofenadine base free of meta isomer of fexofenadine base and fexofenadinone.

Description

INDUSTRIAL PROCESS OF FEXOFENADINE HYDROCHLORIDE WITH CONTROLLED SIDE PRODUCTS
FIELD OF THE INVENTION
The present invention relates to the robust, economically feasible and environmentally friendly manufacturing process of Anhydrous Fexofenadine Hydrochloride (I) with controlled level of side products. There are two aspects of present invention. First, to get the required regio-isomer, i.e., para-isomer (Fexofenadine) by repeated purifications of the crude product. The second aspect of the present invention is to furnish Fexofenadine Hydrochloride with controlled level of water content, i.e., not more than 0.5% using acetone as a solvent of choice for dehydration.
Figure imgf000002_0001
Anhydrous Fexofendine Hydrochloride (I)
BACKGROUND OF THE INVENTION
4-[4-[4-(Hydroxydiphenylmethyl)-l-piperidinyl]-l-hydroxybutyl]-α, α-dimethylbenzene acetic acid of formula (I) (Fexofenadine) hydrochloride is a useful antihistamine, antiallergic agent and bronchodilator (U.S. Patents 4,254,129; 4,254,130 and 4,285,958). A number of patents disclose the syntheses of Fexofenadine Hydrochloride, e.g., U.S. Patents 3,878,217; 3,931,197; 3,941,795; 3,946,022; 4,254,129; 4,254,130; 4,285,957; 4,443,460; 5,375,693; 5,578,610; 5,581,011; 5,589,487; 5,631,375; 5,663,412; 5,750,703; 5,925,761 and 5,990,127. A thorough review of the available literature information reveals that there are two ways to furnish fexofenadine as its pharmaceutically acceptable salt, one is by purification of the intermediates involved hi the synthesis of fexofendine and also the final crude product and the other is by derivatization of the intermediate in such a way that the unrequired product will not contaminate the required isomer of fexofenadine (U.S. Patents 4,254,129; 4,254,130 and 5,578,610).
The present invention relates to a purification method of the crude product to get acceptable quality of Fexofenadine Hydrochloride.
SUMMARY OF THE INVENTION
The present invention reports the robust manufacturing process for the production of Fexofenadine Hydrochloride having less than 1.0% of total impurities and moisture content less than 0.5 % . The characterization of the known impurities, i.e. , Fexofenadone and meta- isomer of Fexofenadine has been done by IR, NMR (1H and C13), LC MS MS and HPLC impurity profile gradient method.
The manufacturing process starts from the α,α-Dimethylphenyl acetic acid. α,α- Dimethylphenyl acetic acid on treatment with methanol in presence of concentrated sulfuric acid in catalytic amount provides the methyl ester of α,α-Dirnethylphenyl acetic acid, i.e., methyl-α , α-Dimethylphenyl acetate .
Further this ester on Fridel - Crafts' , acylation with 4-Chlorobutyryl chloride in presence of anhydrous aluminium chloride in ethylenedichloride (EDC) solvent furnishes the corresponding acylated methyl-α,α-Dimethylphenyl acetate, i.e., ketone intermediate as a mixture having para and meta isomer.
This ketone intermediate on condensation with Azacyclanol in presence of potassium bicarbonate and potassium iodide in aromatic hydrocarbon or dimethylformamide gives the corresponding para and meta isomer of Fexofenadone methyl ester.
The Fexofenadone methyl ester is reduced with sodium borohydride in methanol, which on subsequent alkaline hydrolysis in water methanol mixture gives Fexofenadine having para and meta isomer.
The exclusive separation of para isomer from this isomeric mixture has been done with just two to three times suspensions in methanol : methylethylketone mixture having specific ratio of ingredients. Finally refluxing the material in methanol : dimethylformamide provides Fexofenadine Base having total impurities not more than 1.0% and having moisture content in the range of 2.5 to 6.0% .
Fexofenadine base with moisture content 2.5 to 6.0% on treatment with methanol and aqueous hydrochloric acid gives the corresponding hydrochloride salt which on treatment with acetone at reflux and then cooling provides Anhydrous Fexofenadine Hydrochloride. The product meets all the requirement of the International Conference on Harmonization (ICH) guidelines.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a process for the efficient purification method of Fexofenadine and its hydrochloride salt having less than 1.0% of total impurities and moisture content less than 0.5%. The characterization of the known impurities, i.e., Fexofenadone and meta-isomer of Fexofenadine has been done by IR, NMR (1H and C13), LC MS MS and HPLC impurity profile gradient method. According to one embodiment, the present invention is directed to a manufacturing process of 4-[4-[4-(hydroxydiphenylmethyl)-l-piperidinyl]-l-hydroxybutyl]-α, α- dimethylbenzene acetic acid hydrochloride in pure form. The schematic presentation of synthetic process of fexofenadine hydrochloride is shown in Scheme I.
Figure imgf000005_0001
Alpha-alpha-Dimethyl phenylacetic acid Methyl-alpha-alpha-Dimethyl phenylacetic acid
Figure imgf000005_0002
Ketone (Meta-isomer) Ketone (Para-isomer)
1) Azacyclanol
2) KHCO3
3) KI
Figure imgf000006_0001
(Meta-isomer) (Para-isomer) Methyl ester of Fexofenadine Methyl ester of Fexofenadine
Methyl ester of Fexofenadine (meta and para isomers)
Figure imgf000006_0002
Crude Fexofenadine(Meta-isomer) Crude Fexofenadine(Para-isomer)
Crude F i-eexxoofteennaadαϊinπee (meta and para isomers)
Figure imgf000007_0001
Fexofenadine (Para-isomer) Fexofenadine hydrochloride
Figure imgf000007_0002
Fexofenadine hydrochloride Anhydrous Fexofenadine hydrochloride In the present invention it is observed that crude fexofenadine (meta and para isomers) may be purified by heating it in a mixture of methylethyl ketone and methanol followed by second treatment with dimethylformamide and methanol.
A detailed synthetic process of fexofenadine hydrochloride, an efficient purification method of fexofenadine base and process for making anhydrous fexofenadine hydrochloride are disclosed herein:
(a) Reaction of α,α-Dimethyl phenyl acetic acid and methanol α,α-Dimethylphenyl acetic acid was reacted with methanol in presence of cone, sulfuric acid between about 25 to 45°C. Reaction mixture was refluxed for about 4 hours. Methanol was distilled off after the said time to give thick oily slurry of Methyl-α,α-dimethylphenyl acetic acid. Water was added to the pre-cooled reaction mixture and extracted with chloroform followed by washing with aqueous sodium bicarbonate solution and finally with potable water. Removal of chloroform under reduced pressure yielded title compound as oily mass in about 98 % HPLC purity.
(b) Reaction of Methyl-α,α-dimethylphenyl acetic acid with 4-Chlorobutyryl chloride
Methyl-α,α-dimethylphenylacetic acid on Fridel-Craft's acylation with 4-chlorobutyryl chloride in presence of anhydrous aluminum chloride in ethylene dichloride produced acylated Methyl-α,α-dimethylphenyl acetic acid, i.e., ketone intermediate as meta and para- isomers.
More particularly, aluminum chloride was taken in dichloroethane and cooled in between about 0 to 2O0C. To the above pre cooled solution, Methyl-α,α-dimethylphenyl acetic acid was added at low temperature. To the reaction mixture, 4-chlorobutyryl chloride was added between about 0 to 20°C. After addition of acid chloride the reaction mixture was stirred for about 8 to 10 hours at the same temperature. After completion of the reaction, mixture was quenched over chilled mixture of potable water and cone, hydrochloric acid followed by stirring the reaction mixture for another 4 hours. The reaction mixture was washed with aqueous solution of sodium bicarbonate and finally with water. Removal of dichloromethane provided Methyl-4-(4-chloro-l-oxobutyryl)-α,α-dimethylphenyl acetate (Ketone) in about 95 % HPLC purity.
c) Reaction of Methyl-4-('4-chloro-l-oxobutyryl')-α,α-dimethylphenyl acetate with azacyclanol Two methods were employed for this reaction which are as follows,
Method
Methyl-4-(4-chloro-l-oxobutyryl)-α,α-dimethylρhenyl acetate (Ketone) (meta and para isomers) was dissolved in toluene followed by addition of Azacyclanol and water in presence of potassium carbonate and potassium iodide. Reaction mixture was refluxed for about 30 to 40 hours. After the reaction was completed, reaction mixture was cooled to room temperature and aqueous layer was discarded. Organic layer was filtered through Nutsche and distilled under reduced pressure and degassed for 2 hours to get the oily mass of carbinol, i.e., Methyl-4{4- [4-(hydroxydiphenylmethyl)-l-piperidinyl}-l-oxobutyl]-α, α-diphenylmethyl benzene acetate. Method 2
Methyl-4-(4-Chloro-l-oxobutyryl)-α, α-dimethylphenyl acetate, (Ketone) (meta and para isomers) was dissolved in dimethyl formamide followed by addition of Azacyclnol, potassium carbonate and potassium iodide. The reaction mixture was heated at 9018C for about 7 to 12 hours. Reaction was monitored by HPLC. After the reaction was completed it was cooled to room temperature and the product was extracted with chloroform and was well washed with water. Removal of the organic solvent at reduced pressure yielded thick oily carbinol.
d) Reduction of Carbinol viz, (Methyl-4{4-r4-(hvdroxydiphenyhnetyl)-l-piperidinyl}-l- hydroxybutyll -α , α-dimethylbenzene acetate)
Methyl-4{4-[4-(hydroxydiphenylmetyl)-l-piperidinyl}-l-hydroxybutyl]-α,α- dimethylbenzene acetate (carbinol) obtained as oily mass in example 3 was dissolved in methanol and cooled to about 0 to 20®C followed by addition of sodium borohydride. At the same temperature reaction mass stirred for 2 to 5 hours. After the reduction was completed the reaction mass was stirred at room temperature in presence of water and chloroform. Organic layer was separated followed by rewashing with aqueous layer. Combined organic layer was pooled and washed with potable water and submitted for chloroform distillation under reduced pressure to get thick oily mass of dicarbinol, i.e., Methyl-4{4-[4-(hydroxydiphenylmetyl)-l- piperidinyl}-l-hydroxybutyl]-α,α-dimethyl benzene acetate.
e) Deprotection of carboxyl function of Methyl-4{4-r4-(hydroxydiphenylmetyl)-l-piperidinyl}- l-hvdroxybutyll-α,α-dimethyl benzene acetate to yield crude isomer of Fexofenadine base
The dicarbinol prepared in example 3 was dissolved in methanol followed by addition of sodium hydroxide in potable water followed by refluxed for about 3 to 6 hours. Methanol was distilled off, once the reaction deprotection was completed. The reaction mixture was cooled to room temperature and to it chloroform was added. Reaction mixture was cooled to about 0 to 2O0C. pH of the reaction mass was adjusted to about 6.4 to 6.8 with 50 % aqueous hydrochloric acid solution. Reaction mixture was stirred for 1 hour at the same pH. Chloroform was separated and aqueous layer was washed twice with chloroform. Organic layer was pooled and submitted for distillation under reduced pressure. To the above mass methanol was added and heated 45 to 50°C for about half an hour. The mass was cooled to room temperature and methylethyl ketone was added to it. The crystallized mass was stirred for about 30 to 35 hours at room temperature and centrifuged to get crude fexafenadine base.
f) Purification of Fexofenadine
Fexofenadine (40 Kg) thus isolated from the above step was charged to about 60 to 100 Ltr of a mixture of methanol in methylethyl ketone in volume ratio of 0.3 to 5.0. More particularly, the volume ratio of methanol in methylethyl ketone was 0.4 to 2.0, specifically about 0.4 to 0.6. The reaction mass was refluxed for about 10 minutes to 2 hours, more particularly between about 20 minutes to 40 minutes. After the said time reaction mass was cooled to room temperature followed by stirring for another 1 hour at room temperature. The reaction mixture was centrifuged. The same treatment was repeated twice followed by treatment with dimethyl formamide-methanol and water.
Three times treated fexofenadine base in the above step was charged to about 120 to 180 Ltr of a mixture of methanol in DMF volume ratio of 0.3 to 5.0. More particularly, the volume ratio of methanol was 0.4 to 2.0. More particularly, the volume ratio of methanol in DMF was about 0.4 to 0.6. The reaction mixture was refluxed for about 10 minutes to 2 hours, more particularly between about 30 minutes to 1.5 hours. After the said time reaction mixture was cooled to room temperature and centrifuged.
The wet cake obtained in the above process was taken in water and heated to 50 to 1000C, more particularly between 65 to 850C. The mixture was stirred for about 1 hour and cooled to room temperature. The centrifuged material was centrifuged and dried in fluid bed dryer at 60 to 8O0C for about 5 to 7 hours. Fexofenadine Base (para isomer) having total impurities not more than 1.0% and having moisture content in the range of 2.5 to 6.0% was obtained after employing these purification steps. g) Fexofenadine hydrochloride
Fexofenadine base having moisture content about 2.5 to 6% was taken in methanol and treated with 50 % aqueous HCl to make the pH of the solution between 2.4 to 2.6. The clear solution was filtered to remove any solid contaminant. Chilled potable water was added to the solution at 0 to 20°C. The hydrochloride salt of fexofenadine was obtained as white crystals. Additional volume of water was added to the reaction mixture at the same temperature and stirred for 2 hours. Material was centrifuged and dried.
h) Anhydrous Fexofenadine Hydrochloride
The fexofenadine hydrochloride obtained in the above step was treated with acetone for about 30 minutes to 2 hours between about 4O0C to reflux temperature. The reaction mixture was cooled to 0 to 5°C and centrifuged. Centrifuged material was dried in FBD for 6 to 8 hours at 60 to 8O0C to get the title product having moisture content between about 0.2 to 0.5% .
Examples
The following examples illustrate the invention, but is not limiting thereof,
EXAMPLE 1
Methyl- a, a-Dimethyl phenyl acetate (ester)
51 Kg (0.3109 Kmole) of α,α-Dimethyl acetic acid was dissolved in 100 to 150 Ltr methanol and to it was added concentrated sulfuric acid, 6 to 9 Kg maintaining temperature 25 to 450C. After complete addition of sulfuric acid reaction mixture was refluxed for 4 hours. After completion of the reaction methanol was distilled off under vacuum to obtain thick slurry which was cooled to room temperature and to it was added water. Reaction mixture was then extracted with chloroform and washed with 10% w/v sodium bicarbonate aqueous solution. Finally, chloroform layer was washed with potable water. On removal of chloroform under vacuum, Methyl-α,α-Dimethyl phenyl acetate as oily mass was obtained. HPLC Purity = 98%. Yield = 40 to 50 Kg. EXAMPLE 2
Methyl-4-(4-chloro-l-oxobutyryl)- a, a-dimethyl phenyl acetate (Ketone)
95 Kg (0.7124 Kmole) of aluminium chloride was taken in 120 Ltr dichloroethane and reaction mixture was cooled to 0 to 2O0C. To it was added ester of example 1, 46 Kg (0.2584 Kmole) through addition flask, maintaining the temperature 0 to 200C. Finally, to the reaction mixture was added 80 Kg (0.5673 Kmoles) of 4-chlorobutyryl chloride through addition flask maintaining the temperature 0 to 200C. After addition of acid chloride stirred the reaction mixture at 0 to 200C for 8 to 10 hours. After completion it was quenched over chilled mixture of potable water and concentrated hydrochloric acid. Then stirred the reaction mixture at 0 to 200C for 4 hours and finally extracted in dichloroethane. It was washed with 10% w/v aqueous solution of sodium bicarbonate and finally with water. Removal of the solvent under vacuum provides thick oily mass of Methyl-4-(4-chloro-l-oxobutyryl)-α-α-dimethyl phenyl acetate (Ketone). HPLC purity = 95%. Yield = 65 to 70 Kg.
EXAMPLE 3
Fexofenadine Base Crude
A) Carbinol:(Methyl-4{4-[4- (hydroxydiphenylmetyl)-l-piperidinyl}-l-oxobutyl]- a, a- dimethylbenzene acetate) Method (I)
Methyl-4-(4-chloro-l-oxobutyryl)-α,α-dimethyl phenyl acetate (Ketone), 70 Kg (0.2482 Kmole) was dissolved in 500 to 700 Ltr toluene and to it was added Azacyclanol, 50 to 60 Kg followed by potassium bicarbonate, 74 Kg (0.7391 Kmole) and potassium iodide, 0.50 to 1.20 Kg. Finally, to it was added 53 Ltr water. Reaction mixture was refluxed for 30 to 40 Hours. Completion of the reaction was monitored by HPLC. On completion the reaction mixture was cooled to room temperature and aqueous layer was discarded. Toluene layer was filtered through Nutsche. Finally toluene was distilled under reduced pressure and degassed for 2 hours to get the oily mass of carbinol.
Carbinol:(Methyl-4{4-[4-(hydroxydiphenyhnetyl)-l-piperidinyl}-l-oxobutyl]-a, a- dimethylbenzene acetate) Method (H) Methyl-4-(4-chloro-l-oxobutyryl)-α,α-dimethyl phenyl acetate (Ketone), 0.50 Kg (0.001769 mole) was dissolved in 400 nil dimethylformamide and to it was added Azacyclanol, 0.428 Kg (0.00160 mole) followed by potassium bicarbonate, 0.528 Kg (0.00528 mole) and potassium iodide, 0.00357 Kg. Reaction mixture was heated at 9O0C for 7 to 2 Hours. Completion of the reaction was monitored by HPLC. On completion the reaction mixture was cooled to room temperature and the product was extracted twice with chloroform and finally washed with water. Removal of the solvent at reduced pressure provides thick oily carbinol.
B) Dicarbinol (Methyl-4{4-[4-(hydroxydiphenylmetyl)-l-pipeήdinyl}-l-hydroxybutylJ-a, a- dimethylbenzene acetate)
Above oily mass of Carbinol was dissolved in 600 Ltr methanol and it was cooled to 0 to 200C. To it was added Sodium borohydride, 10 Kg (0.2645 Kmole) in lots. After complete addition, reaction mass was stirred at 0 to 2O0C for 2 to 5 hours. After completion, the reaction mass was stirred at room temperature with 400 Ltr potable water and 200 Ltr Chloroform for 1 hour. Separated chloroform layer. The aqueous layer was again washed with 100 Ltr Chloroform. Combined chloroform extract was washed with potable water and then submitted for chloroform distillation under vacuum to get thick oily mass of dicarbinol.
C) Fexofenadine πVIethyl-4{4-r4-(hydroxydiphenylmetyl)-l-piperidmyl}-l-hydroxybutyll-α,α- dimethylbenzene acetate)
The above oily mass of Dicarbinol was dissolved in 300 Ltr methanol and to it was added 120 to 130 Kg Sodium hydroxide dissolved in 400 Ltr potable water. Reaction mixture was refluxed for 3 to 6 hours. On completion of the reaction the methanol was distilled out under vacuum. Cooled the reaction mixture to room temperature and added 200 to 400 Ltr Chloroform. Finally the reaction mass was cooled to 0 to 200C. Adjusted the pH of the reaction mass 6.4 to 6.8 with 50% aqueous hydrochloric acid solution. At pH 6.4 to 6.8 the reaction mass was stirred for 1 hour and chloroform layer was separated. The aqueous layer was again washed twice with chloroform. Finally chloroform layer was submitted for distillation under vacuum. To the above mass added 30 Ltr methanol and heated at 45 to 5O0C temperature for half an hour. Then cooled the mass to room temperature and added 60 Ltr methylethyl ketone. The crystallization mass was stirred for 30 to 35 hours at room temperature. Then centrifuged the material. The sample was submitted for loss on drying and impurity profile. Yield = 40 to 45 Kg
EXAMPLE 4
Fexofenadine Base Pure
Purification
40 Kg of Crude Fexofenadine Base was charged to a mixture of 30 Ltr methanol and 60 Lr methylethyl ketone. The reaction mass was refluxed for 30 minutes followed by cooling to room temperature. Stirring of the reaction mixture was done at room temperature for 1 hour and was centrifuged the material. Sample was submitted for loss on drying and impurity profile.
Note: The above purification process was repeated twice and finally material was given the treatment with dimethylformamide and methanol followed by water to meet the impurity profile.
Dimethylformamide - Methanol treatment
Fexofenadine base obtained after third purification was treated with a mixture of 100 Ltr dimethylformamide and 50 Ltr methanol and heated at reflux for an hour. Then cooled to room temperature and centrifuged.
The wet cake obtained above was suspended in 300 Ltr potable water and heated to 70 to 750C temperature. The material was stirred for an hour and then cooled to room temperature. Centrifuged the material and dried in fluid bed dryer (FBD) at 60 to 8O0C for 5 to 7 hours. Moisture content = 2.0 to 5.0%. HPLC Purity = 99%. Yield = 25 Kg.
EXAMPLE 5
Fexofenadine Hydrochloride
Fexofenadine Base pure, 25 Kg was suspended in 65 Ltr methanol on reaction mixture was cooled 0 to 2O0C. Then it was added 50% aqueous hydrochloric acid solution to adjust pH 2.4 to 2.6. At pH 2.4 to 2.6 the solution was clear and was filtered through module. To this solution 65 Ltr chilled potable water was added at 0 to 200C. pH was found 2.5. Material was thrown out as white crystals. Again to it 100 Ltr chilled water was added at temperature 0 to 200C. The reaction mixture was stirred for 2 hours. Centrifuged the material. It was dried in FBD at 60 to 800C for 7 to 8 hours till moisture content 2.0 to 6.0% . HPLC purity = 99% . Yield = 24 Kg.
The above material, 24 Kg was treated with acetone, 140 Ltr at reflux for an hour. Then it was cooled 0 to 50C. The material was stirred for 1 hour at 0 to 50C. Centrifuged the material and dried in FBD for 6 to 8 hours at 60 to 8O0C. HPLC purity = 99% . Moisture content = 0.3% . Yield = 23 Kg.

Claims

Claims:
1. A process for purification of a compound of the formula
Figure imgf000016_0001
contaminated with meta isomer and fexofenadinone.
2. The process of claim 1, wherein contaminated fexofenadine base is purified with an organic solvent or mixtures thereof.
3. The process according to claim 2, wherein organic solvents are aliphatic alcohol, amide or ketone.
4. The process according to claim 3, wherein aliphatic alcohols are methanol, ethanol, propanol, isopropanol or n-butanol.
5. The process according to claim 4, wherein more preferable solvent is methanol.
6. The process according to claim 3, wherein amide is dimethyl formamide or dimethyl acetamide.
7. The process according to claim 6, wherein more preferably amide is dimethyl formamide.
8. The process according to claim 3, wherein more preferable ketone is methylethyl ketone.
9. The process according to claim 2, wherein said mixture of organic solvents are methylethyl ketone and methanol.
10. The process according to claim 9, wherein volume ratio of methanol in methylethyl ketone is between about 0.3 to 5.0.
11. The process according to claim 10, more preferably said methanol ratio is between about 0.4 to 0.6.
11. The process according to claim 3, wherein said mixture of organic solvents are aliphatic alcohols and amides.
12. The process according to claim 11, wherein said mixture of organic solvents are methanol and dimethyl formamide.
13. The process according to claim 12, wherein volume ratio of methanol in dimethyl formamdie is between about 0.3 to 5.0.
11. The process according to claim 13, more preferably said methanol ratio is between about 0.4 to 0.6.
12. The process according to claim 2-11, wherein said solid mass is refluxed with water after treatment with organic solvent or mixtures thereof.
13. The process according to claim 1, wherein purified fexofenadine contains less than 0.2 % Fexofenadinone and less than 0.1 % fexofenadine meta isomer.
14. A process of preparing anhydrous form of a compound of formula II
Figure imgf000017_0001
Fexofendine Hydrochloride (II)
15. The process according to claim 14, wherein a compound of formula (II) is refluxed with acetone to get anhydrous compound (II).
16. The process according to claim 14, wherein said anhydrous product of formula (II) obtained in about 0.2 to 0.5 % moisture.
PCT/IN2005/000241 2005-07-07 2005-07-13 Industrial process of fexofenadine hydrochloride with controlled side products WO2007007347A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN809MU2005 2005-07-07
IN809/MUM/2005 2005-07-07

Publications (1)

Publication Number Publication Date
WO2007007347A1 true WO2007007347A1 (en) 2007-01-18

Family

ID=37636776

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000241 WO2007007347A1 (en) 2005-07-07 2005-07-13 Industrial process of fexofenadine hydrochloride with controlled side products

Country Status (1)

Country Link
WO (1) WO2007007347A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034582A2 (en) * 2007-09-13 2009-03-19 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride
WO2009136412A2 (en) * 2008-04-25 2009-11-12 Matrix Laboratories Limited PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF
US7671071B2 (en) 2002-06-10 2010-03-02 Teva Pharmaceutical Industries Ltd. Polymorphic Form XVI of fexofenadine hydrochloride
CN102070490A (en) * 2009-11-21 2011-05-25 浙江华海药业股份有限公司 Method for preparing fexofenadine intermediate 2-(4-(4-maloyl) phenyl)-2-methylpropionitrile
CN102070512A (en) * 2009-11-21 2011-05-25 浙江华海药业股份有限公司 Synthesizing route and preparation method of high-purity fexofenadine and intermediate thereof
JP2012087100A (en) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd Method for producing fexofenadine monohydrochloride of form i

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102777A2 (en) * 2001-06-18 2002-12-27 Dr. Reddy's Laboratories Ltd. NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
US6797826B2 (en) * 1993-06-24 2004-09-28 Amr Technology, Inc. Piperidine derivatives and process for their production
US6903232B2 (en) * 2001-06-25 2005-06-07 Aurobindo Pharma Ltd. Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-α, α-dimethylphenylacetic acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797826B2 (en) * 1993-06-24 2004-09-28 Amr Technology, Inc. Piperidine derivatives and process for their production
WO2002102777A2 (en) * 2001-06-18 2002-12-27 Dr. Reddy's Laboratories Ltd. NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE
US6903232B2 (en) * 2001-06-25 2005-06-07 Aurobindo Pharma Ltd. Process for the preparation of a highly pure pharmaceutical intermediate, 4-(cyclopropylcarbonyl)-α, α-dimethylphenylacetic acid

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671071B2 (en) 2002-06-10 2010-03-02 Teva Pharmaceutical Industries Ltd. Polymorphic Form XVI of fexofenadine hydrochloride
WO2009034582A2 (en) * 2007-09-13 2009-03-19 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride
WO2009034582A3 (en) * 2007-09-13 2010-05-06 Ind-Swift Laboratories Limited Process for the preparation of amorphous fexofenadine hydrochloride
WO2009136412A2 (en) * 2008-04-25 2009-11-12 Matrix Laboratories Limited PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF
WO2009136412A3 (en) * 2008-04-25 2010-03-25 Matrix Laboratories Limited PROCESS FOR PREPARATION OF 4-[4-(4-(HYDROXYDIPHENYLMETHYL)- 1-PIPERIDINYL]-1-OXOBUTYL]-α,α-DIMETHYLBENZENE ACETIC ACID METHYL ESTER AND USE THEREOF
CN102070490A (en) * 2009-11-21 2011-05-25 浙江华海药业股份有限公司 Method for preparing fexofenadine intermediate 2-(4-(4-maloyl) phenyl)-2-methylpropionitrile
CN102070512A (en) * 2009-11-21 2011-05-25 浙江华海药业股份有限公司 Synthesizing route and preparation method of high-purity fexofenadine and intermediate thereof
CN102070490B (en) * 2009-11-21 2014-07-30 浙江华海药业股份有限公司 Method for preparing fexofenadine intermediate 2-(4-(4-maloyl) phenyl)-2-methylpropionitrile
CN102070512B (en) * 2009-11-21 2014-11-19 浙江华海药业股份有限公司 Synthesizing route and preparation method of high-purity fexofenadine and intermediate thereof
JP2012087100A (en) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd Method for producing fexofenadine monohydrochloride of form i

Similar Documents

Publication Publication Date Title
JP4996467B2 (en) Synthesis of N- (4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N '-(4- (2-methylpropyloxy) phenylmethyl) carbamide and its tartrate salt and crystalline form
WO2007007347A1 (en) Industrial process of fexofenadine hydrochloride with controlled side products
JP5503546B2 (en) Separation of 4,5-dimethoxy-1- (methylaminomethyl) -benzocyclobutane
US20160297825A1 (en) Efficient method for the preparation of tofacitinib citrate
JP2008094848A (en) New type 4-[4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzeneacetic acid and hydrochloride thereof
JP2009515945A (en) Improved synthesis and preparation of intermediates and novel polymorphs useful for the preparation of donepezil hydrochloride
JP4344230B2 (en) Process for producing piperidine derivative fexofenadine
JP5585822B2 (en) Method for producing optically active nipecotic acid derivative
EP2507212B1 (en) Process for preparing methyl phenidate hydrochloride
AU2001278094A1 (en) Novel crystalline forms of 4-[4-[4-(hydroxydiphenylmethyl)-1-piperindinyl]-1-hydroxybutyl]-alpha, alpha-dimethylbenzene acetic acid and its hydrochloride
PT2009157006W (en) Processo of preparing ebastine
WO2011161646A2 (en) Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
JP5714748B2 (en) Method for preparing biphenyl-2-ylcarbamic acid ester
WO2014009964A1 (en) Process for enantiomeric enrichment of 2 ', 6 ' - pipecoloxylidide
US6521758B2 (en) Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
EP0123832A1 (en) Process for the optical resolution of a mixture of the enantiomers of trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidine
WO2007052310A2 (en) Polymorphs of fexofenadine hydrochloride and process for their preparation
CN102827152A (en) Method for preparing tiagabine and precursor compound of tiagabine
JP2003515600A (en) Process for producing {2- [4- (α-phenyl-p-chlorobenzyl) piperazin-1-yl] ethoxy} acetic acid and novel intermediates therefor
KR100954755B1 (en) Method for preparing r---1-[4-chloro-phenylphenyl-methyl]piperazine
JP2002371060A (en) Method for producing optically active aminopiperidine derivative
WO2007025696A2 (en) Process for making substituted piperazinyl compounds
US7772437B2 (en) Process of making sertraline form II
WO2019186260A1 (en) An improved process for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
CN113121414A (en) Synthetic method of trelagliptin intermediate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815852

Country of ref document: EP

Kind code of ref document: A1